Cargando…

Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines

BACKGROUND: For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐described range of side effects, which may have a detrimental effect on the patient's quality of...

Descripción completa

Detalles Bibliográficos
Autores principales: Shore, Neal D., Antonarakis, Emmanuel S., Cookson, Michael S., Crawford, E. David, Morgans, Alicia K., Albala, David M., Hafron, Jason, Harris, Richard G., Saltzstein, Daniel, Brown, Gordon A., Henderson, Jonathan, Lowentritt, Benjamin, Spier, Jeffrey M., Concepcion, Raoul
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154535/
https://www.ncbi.nlm.nih.gov/pubmed/32130741
http://dx.doi.org/10.1002/pros.23967
_version_ 1783521840522592256
author Shore, Neal D.
Antonarakis, Emmanuel S.
Cookson, Michael S.
Crawford, E. David
Morgans, Alicia K.
Albala, David M.
Hafron, Jason
Harris, Richard G.
Saltzstein, Daniel
Brown, Gordon A.
Henderson, Jonathan
Lowentritt, Benjamin
Spier, Jeffrey M.
Concepcion, Raoul
author_facet Shore, Neal D.
Antonarakis, Emmanuel S.
Cookson, Michael S.
Crawford, E. David
Morgans, Alicia K.
Albala, David M.
Hafron, Jason
Harris, Richard G.
Saltzstein, Daniel
Brown, Gordon A.
Henderson, Jonathan
Lowentritt, Benjamin
Spier, Jeffrey M.
Concepcion, Raoul
author_sort Shore, Neal D.
collection PubMed
description BACKGROUND: For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐described range of side effects, which may have a detrimental effect on the patient's quality of life, necessitating additional interventions or changes in PC treatment. The risk‐benefit analysis for initiating ADT in PC patients throughout the PC disease continuum warrants review. METHODS: A 14‐member panel comprised of urologic and medical oncologists were chosen for an expert review panel, to provide guidance on a more judicious use of ADT in advanced PC patients. Panel members were chosen based upon their academic and community experience and expertise in the management of PC patients. Four academic members of the panel served as group leaders; the remaining eight panel members were from Large Urology Group Practice Association practices with proven experience in leading their advanced PC clinics. The panel members were assigned to four separate working groups, and were tasked with addressing the role of ADT in specific PC settings. RESULTS: This article describes the practical recommendations of an expert panel for the use of ADT throughout the PC disease continuum, as well as an algorithm summarizing the key recommendations. The target for this publication is all providers (urologists, medical oncologists, radiation oncologists, or advanced practice providers) who evaluate and manage advanced PC patients, regardless of their practice setting. CONCLUSION: The panel has provided recommendations for monitoring PC patients while on ADT, recognizing that PC patients will progress despite testosterone suppression and, therefore, early identification of conversion from castrate‐sensitive to castration resistance is critical. Also, the requirement to both identify and mitigate side effects of ADT as well as the importance of quality of life maintenance are essential to the optimization of patient care, especially as more combinatorial therapeutic strategies with ADT continue to emerge.
format Online
Article
Text
id pubmed-7154535
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher John Wiley and Sons Inc.
record_format MEDLINE/PubMed
spelling pubmed-71545352020-04-14 Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines Shore, Neal D. Antonarakis, Emmanuel S. Cookson, Michael S. Crawford, E. David Morgans, Alicia K. Albala, David M. Hafron, Jason Harris, Richard G. Saltzstein, Daniel Brown, Gordon A. Henderson, Jonathan Lowentritt, Benjamin Spier, Jeffrey M. Concepcion, Raoul Prostate Review Articles BACKGROUND: For specific clinical indications, androgen deprivation therapy (ADT) will induce disease prostate cancer (PC) regression, relieve symptoms and prolong survival; however, ADT has a well‐described range of side effects, which may have a detrimental effect on the patient's quality of life, necessitating additional interventions or changes in PC treatment. The risk‐benefit analysis for initiating ADT in PC patients throughout the PC disease continuum warrants review. METHODS: A 14‐member panel comprised of urologic and medical oncologists were chosen for an expert review panel, to provide guidance on a more judicious use of ADT in advanced PC patients. Panel members were chosen based upon their academic and community experience and expertise in the management of PC patients. Four academic members of the panel served as group leaders; the remaining eight panel members were from Large Urology Group Practice Association practices with proven experience in leading their advanced PC clinics. The panel members were assigned to four separate working groups, and were tasked with addressing the role of ADT in specific PC settings. RESULTS: This article describes the practical recommendations of an expert panel for the use of ADT throughout the PC disease continuum, as well as an algorithm summarizing the key recommendations. The target for this publication is all providers (urologists, medical oncologists, radiation oncologists, or advanced practice providers) who evaluate and manage advanced PC patients, regardless of their practice setting. CONCLUSION: The panel has provided recommendations for monitoring PC patients while on ADT, recognizing that PC patients will progress despite testosterone suppression and, therefore, early identification of conversion from castrate‐sensitive to castration resistance is critical. Also, the requirement to both identify and mitigate side effects of ADT as well as the importance of quality of life maintenance are essential to the optimization of patient care, especially as more combinatorial therapeutic strategies with ADT continue to emerge. John Wiley and Sons Inc. 2020-03-04 2020-05-01 /pmc/articles/PMC7154535/ /pubmed/32130741 http://dx.doi.org/10.1002/pros.23967 Text en © 2020 The Authors. The Prostate published by Wiley Periodicals, Inc. This is an open access article under the terms of the http://creativecommons.org/licenses/by-nc/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
spellingShingle Review Articles
Shore, Neal D.
Antonarakis, Emmanuel S.
Cookson, Michael S.
Crawford, E. David
Morgans, Alicia K.
Albala, David M.
Hafron, Jason
Harris, Richard G.
Saltzstein, Daniel
Brown, Gordon A.
Henderson, Jonathan
Lowentritt, Benjamin
Spier, Jeffrey M.
Concepcion, Raoul
Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
title Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
title_full Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
title_fullStr Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
title_full_unstemmed Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
title_short Optimizing the role of androgen deprivation therapy in advanced prostate cancer: Challenges beyond the guidelines
title_sort optimizing the role of androgen deprivation therapy in advanced prostate cancer: challenges beyond the guidelines
topic Review Articles
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7154535/
https://www.ncbi.nlm.nih.gov/pubmed/32130741
http://dx.doi.org/10.1002/pros.23967
work_keys_str_mv AT shoreneald optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT antonarakisemmanuels optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT cooksonmichaels optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT crawfordedavid optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT morgansaliciak optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT albaladavidm optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT hafronjason optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT harrisrichardg optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT saltzsteindaniel optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT browngordona optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT hendersonjonathan optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT lowentrittbenjamin optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT spierjeffreym optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines
AT concepcionraoul optimizingtheroleofandrogendeprivationtherapyinadvancedprostatecancerchallengesbeyondtheguidelines